A Phase 1 Study of Alpelisib (BYL719), an Α- Specific PI3K Inhibitor, in Japanese Patients With Advanced Solid Tumors
Cancer Science - United States
doi 10.1111/cas.13923
Full Text
Open PDFAbstract
Available in full text
Date
January 30, 2019
Authors
Publisher
Wiley